Ramipril Capsule
Product Images NDC 70518-3038

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 70518-3038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Ramipril is a medication available in capsule form with a concentration of 10mg. The package comes with 90 capsules that are only available through a prescription. The medication was manufactured by Aurcbindo Pharma Ltd in Hyderabad, India. The package insert should be consulted for directions for use. The medication should be stored between 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. The medication's lot number, NDC #, and expiration date are not available. It is advised to keep the medication out of the reach of children. The package was repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

This appears to be a graph or chart with the title "Ramipril" and a scale on the x-axis labeled "Days of Follow-up" ranging from 0 to 1500. The y-axis is not labeled but has tick marks for 0.0, 0.1, and 0.2. There are five data points, at approximately 500-day intervals, with values of 0.2, 0.1, 0.1, 0.0, and 0.0 respectively. There is also a note indicating that P=0.0001. It is possible that this represents a study or experiment measuring the proportion of patients experiencing some outcome over time while taking ramipril.*

FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

This text appears to be a table with information about patients and various medical conditions including cardiovascular disease, diabetes, hypertension etc. The table also includes information about the number of patients and incidence of composite outcome in the placebo group. The relative risk in the Ramipril group is also mentioned with a 95% confidence interval.*

FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.